Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer
Hiroo Imai, Ken Saijo, Keigo Komine, Yoshifumi Kawamura, Sakura Hiraide, Sho Umegaki, Yoshinari Okada, Kota Ohuchi, Yuko Sato, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan Purpose:...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/predictive-factors-for-the-efficacy-of-the-second-taxane-treatment-in--peer-reviewed-article-CMAR |
| _version_ | 1818142648106483712 |
|---|---|
| author | Imai H Saijo K Komine K Kawamura Y Hiraide S Umegaki S Okada Y Ouchi K Sato Y Takahashi M Takahashi S Shirota H Takahashi M Ishioka C |
| author_facet | Imai H Saijo K Komine K Kawamura Y Hiraide S Umegaki S Okada Y Ouchi K Sato Y Takahashi M Takahashi S Shirota H Takahashi M Ishioka C |
| author_sort | Imai H |
| collection | DOAJ |
| description | Hiroo Imai, Ken Saijo, Keigo Komine, Yoshifumi Kawamura, Sakura Hiraide, Sho Umegaki, Yoshinari Okada, Kota Ohuchi, Yuko Sato, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan Purpose: Research has revealed that some patients who develop resistance to the first taxane treatment exhibit a moderate response to the second taxane treatment (incomplete cross-resistance between paclitaxel and docetaxel). However, which patients are most likely to respond to the second treatment remains unclear. The aim of this study was to determine the predictive factors for the efficacy of the second taxane treatment in patients resistant to the first.Patients and methods: We enrolled patients treated with paclitaxel and docetaxel (n=31) in this study. Using univariate and multivariate analyses, we determined the predictive factors for the efficacy of the second taxane treatment. Then, we assigned patients to one of the three groups: 1) those with a partial response (PR) to the first taxane treatment who subsequently became refractory (PR group); 2) those whose response was stable disease (SD) and subsequently became refractory (SD group); and 3) those whose response was the progression of the disease with the first taxane treatment (progression disease [PD] group). Furthermore, the response rates were assessed for each group. All statistical analyses were performed using JMP 11.Results: Responses to the first taxane treatment considerably correlated with the efficacy of the second treatment in patients with a PR to the first taxane treatment (P=0.0061, univariate analysis; P=0.0056, multivariate analysis). In addition, response rates to the second taxane treatment in the PR, SD, and PD groups were 33.3%, 0%, and 0%, respectively.Conclusion: The response to the first taxane treatment was a predictive factor for the efficacy of the second taxane treatment in patients with a PR to the first. Thus, the second treatment is highly recommended for patients who exhibit tumor shrinkage (a PR) by the first treatment. Keywords: taxane, predictive factor, univariate analysis, multivariate analysis |
| first_indexed | 2024-12-11T11:19:07Z |
| format | Article |
| id | doaj.art-e664a0aa866844839f1d5403a5922a7d |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-11T11:19:07Z |
| publishDate | 2018-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-e664a0aa866844839f1d5403a5922a7d2022-12-22T01:09:14ZengDove Medical PressCancer Management and Research1179-13222018-09-01Volume 103629363640621Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancerImai HSaijo KKomine KKawamura YHiraide SUmegaki SOkada YOuchi KSato YTakahashi MTakahashi SShirota HTakahashi MIshioka CHiroo Imai, Ken Saijo, Keigo Komine, Yoshifumi Kawamura, Sakura Hiraide, Sho Umegaki, Yoshinari Okada, Kota Ohuchi, Yuko Sato, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan Purpose: Research has revealed that some patients who develop resistance to the first taxane treatment exhibit a moderate response to the second taxane treatment (incomplete cross-resistance between paclitaxel and docetaxel). However, which patients are most likely to respond to the second treatment remains unclear. The aim of this study was to determine the predictive factors for the efficacy of the second taxane treatment in patients resistant to the first.Patients and methods: We enrolled patients treated with paclitaxel and docetaxel (n=31) in this study. Using univariate and multivariate analyses, we determined the predictive factors for the efficacy of the second taxane treatment. Then, we assigned patients to one of the three groups: 1) those with a partial response (PR) to the first taxane treatment who subsequently became refractory (PR group); 2) those whose response was stable disease (SD) and subsequently became refractory (SD group); and 3) those whose response was the progression of the disease with the first taxane treatment (progression disease [PD] group). Furthermore, the response rates were assessed for each group. All statistical analyses were performed using JMP 11.Results: Responses to the first taxane treatment considerably correlated with the efficacy of the second treatment in patients with a PR to the first taxane treatment (P=0.0061, univariate analysis; P=0.0056, multivariate analysis). In addition, response rates to the second taxane treatment in the PR, SD, and PD groups were 33.3%, 0%, and 0%, respectively.Conclusion: The response to the first taxane treatment was a predictive factor for the efficacy of the second taxane treatment in patients with a PR to the first. Thus, the second treatment is highly recommended for patients who exhibit tumor shrinkage (a PR) by the first treatment. Keywords: taxane, predictive factor, univariate analysis, multivariate analysishttps://www.dovepress.com/predictive-factors-for-the-efficacy-of-the-second-taxane-treatment-in--peer-reviewed-article-CMARtaxanepredictive factorunivariate analysismultivariate analysis |
| spellingShingle | Imai H Saijo K Komine K Kawamura Y Hiraide S Umegaki S Okada Y Ouchi K Sato Y Takahashi M Takahashi S Shirota H Takahashi M Ishioka C Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer Cancer Management and Research taxane predictive factor univariate analysis multivariate analysis |
| title | Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| title_full | Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| title_fullStr | Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| title_full_unstemmed | Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| title_short | Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| title_sort | predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer |
| topic | taxane predictive factor univariate analysis multivariate analysis |
| url | https://www.dovepress.com/predictive-factors-for-the-efficacy-of-the-second-taxane-treatment-in--peer-reviewed-article-CMAR |
| work_keys_str_mv | AT imaih predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT saijok predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT kominek predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT kawamuray predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT hiraides predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT umegakis predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT okaday predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT ouchik predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT satoy predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT takahashim predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT takahashis predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT shirotah predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT takahashim predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer AT ishiokac predictivefactorsfortheefficacyofthesecondtaxanetreatmentinpatientswithadvancedcancer |